NCT05703542View on ClinicalTrials.gov

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

March 17, 2026

Study Completion Date

July 31, 2026

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2

Interventions

DRUG

BXCL701

Tablet, taken Orally

Trial Locations (1)

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors

lead

Eric Stephen Winer, MD

OTHER